Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 22, Number 3—March 2016
Online Report

Global Progress and Challenges in Implementing New Medications for Treating Multidrug-Resistant Tuberculosis

Jennifer FurinComments to Author , Grania Brigden, Erica Lessem, Michael Rich, Laura Vaughan, and Sharonann Lynch
Author affiliations: Harvard Medical School, Boston, Massachusettes, USA (J. Furin); Médecins Sans Frontières Access Campaign, Geneva, Switzerland (G. Brigden, S. Lynch); Treatment Action Group, New York, NY, USA (E. Lessem); Brigham and Women’s Hospital, Boston (M. Rich); Partners In Health, Boston (M. Rich, L. Vaughan)

Main Article

Table 3

Alphabetical list of core organizations participating in DR-TB STAT

National TB program director Implementing partner Technical assistance provider Donor Advocacy group
Global Drug Facility
Clinton Foundation
Global Fund for AIDS, TB, and Malaria
Global Coalition of TB Activists

Management Sciences for Health/Systems for Improved Access to Pharmaceutical and Services
Global TB Community Advisory Board
Russian Federation
KNCV Tuberculosis Foundation
Stop TB Partnership
US Agency for International Development

South Africa
Médecins Sans Frontières
Society Working on Implementation to Fight TB Response Project

Moldovan Society Against Tuberculosis
Partners in Health
World Health Organization


Treatment Action Campaign

Treatment Action Group
*DR, drug-resistant; STAT, Scale-up Treatment Action Team; TB, tuberculosis.

Main Article

Page created: February 18, 2016
Page updated: February 18, 2016
Page reviewed: February 18, 2016
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.